Clinical Trials Browser

Phase NA × Recruiting × Everolimus × Clear all

NCT06317298 2024-03-19

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Phase NA Recruiting

Carcinoma, Renal Cell